Actively Recruiting
Positron-Emission Tomography Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
Led by Jonsson Comprehensive Cancer Center · Updated on 2025-11-10
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
J
Jonsson Comprehensive Cancer Center
Lead Sponsor
L
LUNGevity Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating a new type of positron emission tomography (PET) scan using a special tracer called Me-4FDG to detect lung cancer early. This phase I/II clinical trial focuses on lung adenocarcinoma and aims to assess both the safety and effectiveness of the Me-4FDG tracer in identifying cancer cells by tracking glucose uptake through the sodium-glucose transport protein (SGLT2). Understanding this method may help improve early diagnosis of lung cancer. Participants receive an intravenous injection of the Me-4FDG tracer followed by a PET/CT scan lasting about 15 minutes. The trial includes both patients with confirmed lung adenocarcinoma and those with lung nodules considered benign based on imaging guidelines. After the scan, patients are monitored for any adverse effects and followed up seven days later. During the study, researchers measure how sensitive and specific the Me-4FDG PET scans are in detecting lung cancer, comparing results with surgical or biopsy findings. They also examine how tracer uptake relates to tumor grade and expression of SGLT2 in tissue samples. Safety is monitored from the time of tracer injection to one week afterward. The total participation involves the initial scan and a follow-up visit about one week later.
CONDITIONS
Brief Title
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Lung nodule 1 cm or larger seen on CT imaging
- For the cancer group: pathologically confirmed lung adenocarcinoma, either by surgical specimen or needle biopsy for non-surgical patients
- For the benign group: lung nodules considered clinically benign based on Fleischner Society guidelines with a lung-RADS score of 1-3
You will not qualify if you...
- Pregnancy
- Diagnosis of diabetes
- Current treatment with SGLT2 inhibitors or metformin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive an intravenous injection of Me-4FDG tracer followed by a PET/CT scan lasting approximately 15 minutes to assess lung nodules.
1 visit (in-person)
Duration - 7 days
Participants are followed up to monitor safety and any adverse events after the diagnostic evaluation.
1 follow-up visit (in-person)
Trial Site Locations
Total: 1 location
1
Yesenia Calzada
Los Angeles, California, United States, 90095
Actively Recruiting
Research Team
Y
Yesenia Calzada
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here